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Streptavidin-Enzyme Linked Aggregates for the One-Step 
Assembly and Purification of Enzyme Cascades 
 Hendrik Mallin*[a] and Thomas R. Ward*[a] 
 
Abstract: Herein, we report on enzyme aggregates assembled 
around covalently cross-linked streptavidin tetramers. The 
streptavidin oligomeric matrix (SavMatrix) is produced using the 
SpyTag – SpyCatch technology and binds tightly to fusion proteins 
bearing a streptavidin-binding peptide (SBP). Fusing the SBPs to 
different enzymes leads to precipitation of the streptavidin-enzyme 
aggregates upon mixing the complementary components. This 
straightforward strategy can be applied to crude cell-free extract, 
allowing the one-step assembly and purification of catalytically active 
aggregates. Enzyme cascade assemblies can be produced upon 
adding different SBP-fused enzymes to the SavMatrix. The reaction 
rate for lactate dehydrogenase (LDH) is improved tenfold (compared 
to the soluble enzyme) upon precipitation with the SavMatrix from 
crude cell-free extracts. Additionally, the kinetic parameters are 
improved. A cascade combining a transaminase with LDH for the 
synthesis of enantiopure amines from prochiral ketones displays 
nearly threefold rate enhancement for the synthesis of (R)-α-
methylbenzylamine compared to the free enzymes in solution.  
Introduction 
Enzymes have been used for several decades for the production 
of both bulk and high added-value compounds.[1] Thanks to 
significant progress in protein engineering and directed evolution, 
the so-called third wave of biocatalysts has begun to supplant 
established industrial processes.[2] Reactor design and 
immobilization strategies have also played a critical role in the 
recent success of industrial biotechnology.[3] Finally, the 
integration of complex pathways in production strains by 
metabolic engineering enables the production of both high-
added value and bulk chemicals. This is achieved by 
engineering enzyme cascades.[4] The impact of biocatalysis on 
the production of industrial and pharmaceutically-relevant 
compounds are illustrated by the following selected examples: 
artemisinic acid (Sanofi-Aventis), 1,4-butane diol (Genomatica) 
and the Nylon-6 process (DSM).[5]  
Efficient reaction pathways in nature often rely on the close 
proximity of the partner enzymes or on compartmentalization 
with sequential or cascade reactions. This prevents intermediate 
accumulation and side reactions as illustrated in glycolysis or the 
TCA-cycle.[6] High reactions rates are achieved thanks to the 
guided assembly- and scaffolding of the enzymes. Mimicking 
such enzyme assemblies and their application in systems 
biocatalysis is an active area of investigation.[7] For example, 
Dueber et al. designed a recombinant E. coli strain integrating 
an overexpressed mevalonate pathway by the use of specific 
protein-protein interaction domains on a specific protein 
scaffold.[8] The resulting reaction rates of the cascade were 
improved by 77 fold in vivo. Other elegant examples rely on 
designer cellulosomes or DNA scaffolds.[9] Such protein or DNA 
scaffolds allow to simply mix these components with the target 
enzymes to spontaneously afford the desired assembly. 
Insoluble aggregates are of special interest as they can be 
readily isolated by centrifugation to afford a purified solid 
displaying a desired activity. Insoluble cross-linked enzyme 
aggregates (CLEAs) are formed by mixing crude cell extracts 
with glutaraldehyde.[10] Despite their simplicity, these methods 
suffer from the unspecificity of the cross-linking step, which is 
best applied to (semi)-purified enzyme samples. Furthermore, 
structurally- or catalytically relevant lysine residues may react 
with glutaraldehyde thus leading to inactive CLEAs.[11] 
Alternatively, deactivation could result from the shortness of the 
glutaraldehyde spacer, limiting the access to the substrate to the 
active site of the immobilized enzymes or leading to (partial) 
denaturation of the enzyme.  
In the approach presented herein, we set out to design an inert 
protein scaffold that would present highly specific binding 
moieties allowing to precipitate enzymes bearing a 
complementary binding motif. For this purpose, we selected the 
mature T7-tagged full-length streptavidin (Sav hereafter) as 
scaffolding protein. Thanks to its remarkable affinity for biotin 
and stability, Sav is used in many applications.[12] This versatile 
“molecular velcro” offers two key features: 1) Mature T7-tagged 
full-length Sav is highly soluble and can be expressed in high 
yield in E. coli with up to 8.3 g·Lculture broth-1.[13] This contrasts with 
core streptavidin which is produced as inclusion bodies. 2) In 
addition to its biotin-binding affinity, Sav binds streptavidin 
binding peptides (SBP hereafter) with high specificity and affinity. 
These short N- or C-fused peptides (e.g. Streptag, Nanotag, 
SBP-tag) are biocompatible and have found a broad range of 
application in biotechnology.[14] Sinclair et al. described the 
formation of 2D-protein lattices from core Sav with StreptagI- 
tagged proteins.[15] Although enzymes were used for this study, 
no information on the catalytic activity of the resulting 2D-
network was provided. The resulting assemblies were small and 
poorly ordered arrays were achieved.[16] Herein, we report on 
our efforts to create enzyme aggregates relying on a streptavidin 
matrix amenable to the precipitation of enzymes from crude 
samples. 
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Results and Discussion 
We hypothesized that cross-linking a highly soluble Sav may 
result in a (soluble) Sav matrix (SavMatrix hereafter) that could 
maintain its biotin binding sites available for subsequent 
anchoring and precipitation of SBP-tagged proteins. This may be 
achieved upon mixing crude cell free extract (CFE hereafter) 
containing the SavMatrix with CFE of SBP tagged enzymes 
(Scheme 1).  
For the design of the oligomeric and functional Sav matrix from 
Sav tetramers, we selected the Spy-Tag/Spy-Catch domains 
from fibronectin-binding protein FbaB from Streptococcus 
pyogenes. This versatile system was adopted in view of its 
robust and rapid covalent isopeptide bond formation between 
the Catch- and the Tag domain in CFE.[17] This covalent bond 
formation was shown to work equally well in in vitro and in vivo. 
By placing the Spy-Tag or the Spy-Catch fragments either at the 
C- or the N-terminus of Sav, we anticipated that SBP-containing 
proteins may still bind the SavMatrix. Upon mixing both SavMatrix 
and crude SBP-tagged enzymes, a catalytically active and 
insoluble aggregate may result. Three challenges were identified 
in this context:  
i) Can a soluble SavMatrix be produced relying on the 
SpyCatch-Tag domains?  
ii) Can this matrix be cross-linked by SBP-tagged 
enzymes resulting in insoluble, enzyme 
aggregates? 
iii) Can different SBP-tagged enzymes be 
simultaneously precipitated with the SavMatrix to 
achieve immobilized cascade reactions?		
 
Scheme 1. Schematic representation of an artificial protein aggregate using a 
designed soluble oligomeric streptavidin matrix and SBP-tagged enzymes as 
building blocks. The multimeric enzymes act as cross-linker between the 
streptavidin matrix. The matrix is covalently assembled using the Spy-Tag-
Catch protein interaction domains fused to streptavidin. 
 
 
Design of a Streptavidin Spy-Tag/ Spy-Catch Matrix  
For SavMatrix design, soluble oligotetrameric streptavidin 
assemblies were prepared using the Spy-Catch-Tag domains 
from fibronectin-binding protein FbaB from Streptococcus 
pyogenes.[17-18] This Spy-Tag-Catch system was selected in view 
of its robustness (against extreme pH, detergents etc.), fast 
covalent isopeptide bond formation and broad applicability. 
Furthermore, remarkable examples of enzyme-stabilization by 
cyclisation or attachment to E. coli nanofibers are reported using 
the Spy-Tag/Spy-Catch technology.[19] 
The SavMatrix was produced in vitro by combining E. coli CFE of 
Sav fused to the Spy-Tag-domain (SavSpyTag hereafter) with Sav 
CFE fused to the Spy-Catch-domain (SavSpyCatch hereafter). 
Mixing both components leads to the spontaneous formation of 
a covalent isopeptide bond between the tag- and catch domain 
even in crude cell extracts. Thanks to the tetrameric nature of 
Sav, oligomeric structures should be formed (i.e. consisting of at 
least two tetramers). For the Spy-Catch domain, an optimized 84 
amino acid long version (i.e. 32 amino acid shorter than wild-
type) was selected for optimal expression yields.[18] The Tactin 
mutation (amino acids loop E44-S45-A46-V47 within Savwildtype 
mutated to E44V-S45T-A46-V47R) was introduced into the Sav 
to increase its affinity for the Streptag II.[20] First, the best protein 
termini (N- or C-) for fusion of the Spy-Tag or Spy-Catch domain 
to Sav were explored. The domains were fused to Sav using a 
ten amino acid linker (GGSIDGRGGS). The N-terminal SavSpyTag 
with the N-terminal SavSpyCatch gave the best yield of SavMatrix and 
were thus used for the rest of the study (See SI, Figure S1 and 
Table S3). Following this procedure, soluble oligotetramers of 
varying sizes (Figure S1, > 170 kDa) were formed thanks to the 
spontaneous isopeptide bond formation between the Spy-Tag 
and the Spy-Catch interaction domains.  
Analytical size-exclusion chromatography of the SavSpyTag or 
SavSpyCatch single components (Table SI 5) revealed SavSpyTag 
and SavSpyCatch tetramers within the E. coli CFE (Table SI 5). 
Upon mixing both Sav components in equimolar ratio, very little 
residual Sav tetramers were detected by SDS-PAGE and size 
exclusion chromatography. This confirmed the versatility of the 
spontaneous covalent assembly even in the presence of cellular 
debris (Figure S1). Importantly, all Sav constructs, including the 
SavMatrix, bind biotin-4-fluorescein (B4F hereafter) on SDS-PAGE, 
highlighting the properly folded and accessible Sav binding 
pocket, despite the presence of chaotropic SDS. In view of the 
exquisite selectivity of the SBP-tags and the high concentration 
of soluble Sav in the CFE after expression, the crude SavMatrix 
containing-solutions was used for subsequent enzyme 
precipitation studies. 
Enzyme Selection and Design 
To investigate the ability of the SavMatrix to bind SBP-tagged 
proteins and form aggregates, six enzymes were selected 
(Scheme 2): A) A (R)-transaminase from Neosartorya fischeri 
((R)-TA hereafter, dimeric) and a (S)-selective transaminase 
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from Chromobacterium violaceum ((S)-TA hereafter, dimeric), B) 
an alcohol dehydrogenase from Lactobacillus kefir (ADH 
hereafter, tetrameric), C) a lactate dehydrogenase from Bacillus 
stearothermophilus (LDH hereafter, dimeric according to SEC 
analysis), D) a phenylacetone monooxygenase from 
Thermobifida fusca (BVMO-Tf hereafter, monomeric) and E) a 
cyclohexanone monooxygenase from Acinetobacter 
calcoaceticus (BVMO-Ac hereafter, monomeric). These 
enzymes were tagged with two different streptavidin binding 
peptides: i) either the Streptag-II (SII- hereafter) or ii) the SBP-II 
tag. i) The Streptag-II is an eight amino acid peptide which binds 
with µM affinity to one Sav binding pocket and ii) The SBPII-tag, 
a 25 amino acid sequence, binds simultaneously to two adjacent 
Sav binding pockets with nM affinity. A limitation using 
genetically-encoded peptide tags is that the modification of the 
terminus could influence the enzyme's performance and 
expression. It is crucial to initially test the best termini or to rely 
on literature precedent. References using peptide tags to purify 
a specific enzyme may help in selecting the right termini. In the 
context of cascades, a reduction of the activity of the first 
enzyme could have a high negative impact on the final product 
yield. 
All tested enzymes could be genetically tagged with the SII at 
their N-terminus. For LDH and (S)-TA additional variants were 
produced that included both SII and SBPII (N-terminal: Streptag-
II and C-terminal: SBP-II, LDH-double and (S)-TA-double 
hereafter). This resulted in different binding behavior of the 
different enzyme variants depending on their quaternary 
structure (Table S4). A single SII-tagged enzyme monomer is 
expected to bind to only one Sav biotin binding pocket whereas 
the doubly tagged version can bind up to three pockets per 
monomer (SII- binds one and SBPII-tag binds two pockets).   
Scheme 2. Enzymatic reactions and corresponding cascade investigated in 
this study. A) Kinetic resolution of racemic amines with an (R)- or (S)- selective 
TA. The acetophenone product is readily detected 245 nm.[21] B) 
Acetophenone reduction to (R)-1-phenylethanol with an alcohol 
dehydrogenase. C) Pyruvate reduction L-lactate with a lactate dehydrogenase. 
D) Baeyer-Villiger oxidation of phenylacetone to benzyl acetate with BVMO-Tf. 
E) Baeyer-Villiger oxidation of cyclohexanone to ε-caprolactone with BVMO-Ac. 
For B) to E) monitoring of the reaction progress is achieved by 
spectrophotometry 340 nm reflecting the concentration of NAD(P)H. F) A three 
enzyme cascade for the synthesis of enantiopure amines from prochiral 
ketones. Both (R)-TA and LDH bear an SBP-tag while commercial glucose 
dehydrogenase were used. 
Except for glucose dehydrogenase used for the regeneration of 
NAD+ to NADH, all other enzymes were engineered to include 
Sav-binding peptides (Table S4). The recombinant 
overexpression was performed in E. coli BL21 (DE3). The 
resulting activities of the enzymes selected for further studies 
are collected in Table S4. The concentration of the 
overexpressed tagged-enzymes in the CFE was determined 
using a quantitative SDS-PAGE analysis for all samples.  
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Aggregates containing single enzymes 
In an initial screen, each enzyme was incubated individually with 
the SavMatrix. Mixing was performed using equimolar amounts of 
enzyme and Sav free biotin binding sites (0.5 mM Sav 
monomer). The SavMatrix was mixed with the CFE containing the 
SII-enzyme. After incubation for three hours at 4 °C in the 
presence of SavMatrix, a turbid suspension was obtained for all 
enzymes except for the monomeric BVMOs (Figure S2, A and B 
examples given). Upon mixing with SavMatrix, the (S)-TA-double 
precipitated but the LDH-double remained in solution.  
A solid pellet was obtained after centrifugation. To remove 
residual, unspecifically-bound proteins from the aggregates, the 
pellets were subjected to three consecutive washing steps using 
the corresponding enzyme buffers. The washing fractions were 
analyzed by SDS-PAGE and the protein content was determined 
(Figure S3): Nearly no residual protein was detected in the third 
fraction and only minimal amounts were present in the first two 
fractions. This suggests that two washing steps are sufficient to 
remove any unspecifically-bound enzyme. No detectable 
decrease in the pellet weight was observed during washing. This 
was determined by weighting the wet pellet (triplicates). 
Table 1. Summary of the initial activities of the enzyme aggregates. The 
activity was determined at 30°C.  
Entry Enzyme 
variant 
U g-1 dry 
aggregate 
[a, b]  
Recovered 
activity % [c] 
Precipitation 
Efficiency % 
[d] 
1 LDH 167156 ± 
2340 
1086 31 
2 ADH 5220 ± 489 111 74 
3 (R)-TA 7986 ± 275 118  70 
4 (S)-TA 1767 ± 29 44  6  
5 (S)-TA-
double 
7068 ± 98 163 56 
6 LDH 
purified 
246188 ± 
8546 
452 68 
7 (R)-TA 
purified 
7390 ± 247 93 65 
[a] Activity calculated for the whole protein aggregate amount (including 
enzyme and Savmatrix). [b] Activity determined using 30 mM pyruvate (LDH), 
10 mM acetophenone (ADH), 5 mM (R)-α-MBA ((R)-TA) or 5 mM (S)-α-
MBA ((S)-TA). [c] Calculated by comparing the reduced activity from the 
supernatant after precipitation with the activity determined in the 
precipitate; [d] Calculated by comparing the activity of the supernatant after 
precipitation with the total activity prior to precipitation. Reaction conditions: 
1 to 4 ml reaction volume (depending on activity), 5 to 50 µL of precipitate-
enzyme suspension, 30°C (water temperate) using a VarianScan, buffers 
were preheated to 30°C, 2 to 5 min reaction time, Table S2 contains the 
corresponding enzyme buffers and pH.  
The initial activity of the aggregates was determined using 
standard substrates (Table S2, Scheme 2). Initial activity tests 
using LDH aggregate resuspended by a short sonication step 
(10 s sonication, 5 cycles, 30% power) resulted in a twenty five-
fold increased activity compared to the aggregate resuspended 
by pipetting. This effect could be observed for the other 
enzymes as well. However, it was less pronounced. As no 
detrimental effect was ever observed, this sonication step was 
systematically implemented prior to the activity-determination. 
We believe this results in an improved homogeneity of the 
solution and accessibility of the enzymes.  The highest activities 
(Table 1, entry 1 and 3) were obtained with the LDH and (R)-TA 
aggregates. Good activities were also obtained for the ADH and 
the (S)-TA-double (Table 1, entry 2 and 5). The activity of the 
(S)-TA was significantly lower (Table 1, entry 4) highlighting the 
better performance of the (S)-TA-double. The initial screen of 
the enzyme variants highlighted the generality of the method as 
all tested multimeric enzymes could be precipitated resulting in 
high volumetric enzymatic activity and with full recovery of the 
activity (calculated from units absent from the supernatant after 
precipitation versus units in the aggregate). Freeze-drying of the 
enzyme suspensions (resuspended in the corresponding 
enzyme buffer after washing of the aggregate) offers a 
straightforward means to store the aggregates: No loss of 
activity was observed for the freeze-dried LDH. All aggregates 
could be stored in 50 % glycerol at -20 °C. The glycerol is easily 
removed by centrifugation and washing. Short-term storage up 
to two weeks at 4 °C is possible for all aggregates.  
For the rest of the study, the LDH and the (R)-TA were selected 
as benchmark enzymes for the formation of aggregates. Both 
were isolated from thermophile organisms and displayed good 
precipitation properties. They were obtained in sufficient 
amounts by recombinant expression in E. coli. Accordingly, the 
LDH and (R)-TA were recombinantly expressed and purified by 
Streptag affinity chromatography. Upon mixing purified LDH with 
the SavMatrix, the LDH aggregates displayed 47 % higher 
volumetric activity and higher efficiency (twice as high compared 
to CFE, Table 1, entry 1 and 6). The efficiency was calculated by 
comparing the reduced activity of the supernatant after 
precipitation to the initial activity of the enzyme prior to 
precipitation: 100 % refers to no activity in the supernantant after 
precipitation.  Aggregates from CFE containing (R)-TA displayed 
comparable activities to those resulting from purified (R)-TA 
(Table 1, entry 3 and 7).  
Next, free- and aggregated (R)-TAs were tested for the 
asymmetric amine synthesis from prochiral ketones (Scheme 2, 
F). To shift the equilibrium to the amine, soluble glucose 
dehydrogenase (GDH) was combined with LDH. Commercial 
rabbit muscle LDH was used as we anticipated that the SII-
tagged LDH may displace the (R)-TA bound to the SavMatrix. Both 
acetophenone and 2-hexanone were selected as benchmark 
substrates. After 48 h, comparable conversions and 
enantioselectivities were obtained for the free- and (R)-TA 
aggregates. This highlights that the (R)-TA performance is not 
negatively affected upon formation of the aggregate.  
For the LDH aggregate, a tenfold improvement in activity was 
observed using LDH CFE. A less pronounced improvement (4.5 
fold) was obtained for the purified LDH. Next, the kinetic 
parameters for the free LDH and the LDH aggregates were 
determined for both pyruvate and NADH (Table 2). 
Table 2. Kinetic parameters of LDH and LDH aggregates for pyruvate and 
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NADH.[a]  
Entry LDH 
sample 
Substrate[b] Km 
[mM] 
kcat 
[s-1] 
kcat/Km  
(s-1·µM-1) 
Ki 
[mM] 
1 Free 
purified 
Pyruvate 14.6 ± 
4.6 59 
4,046 119 
± 5 
2 Aggregate Pyruvate 5.7 ± 3.4 98 17,164 
94 ± 
5 
3 Free 
purified 
NADH 0.13 ± 
0.03 
74 572,718 - 
4 Aggregate NADH 0.055 ± 
0.007 
135 2,450,078 - 
[a] Values were determined by monitoring the decrease in absorbance of 
NADH at 340 nm and 30°C. [b] For the saturation kinetics analysis, both 
pyruvate and NADH were added to the LDH, and a single substrate 
concentration was varied at a time. Apparent kinetics are given.  
Reaction conditions: 4 ml reaction volume, 30°C (water temperate) using a 
VarianScan, MES-Buffer (100 mM, pH 6.5) was preheated to 30°C, 5 min 
reaction time, reaction was initiated by addition of 50 µL of purified free LDH 
or precipitate-LDH suspension (13 µg ml-1) followed by immediate mixing. 
 
Regarding pyruvate (Table 2, entry 1 and 2), the aggregate 
outperformed the free LDH: the Km decreased by 2.6 fold, the 
kcat improved by 1.7 fold; accordingly the kcat / Km increased by 
4.2 fold. For NADH (Table 2, entry 3 and 4), the same trend was 
observed: The Km decreased by 2.4 fold, the kcat improved by 
1.8 fold and the kcat / Km by 4.3 fold. The improvement for the kcat 
/ Km values were congruent with the observed improved 
performance of the aggregate obtained with the purified LDH 
(Table 1, entry 6, 4.5 fold). Although the observed difference 
between free and aggregated LDH for the Km value for pyruvate 
was within the experimental error, the same trend in Km 
decrease was observed using NADH as benchmark substrate. 
The LDH displays substrate inhibition at high pyruvate 
concentrations[22]. NADH binds first to LDH, followed by pyruvate 
to form the catalytically active complex. After reduction, the 
LDH-NAD+-lactate complex is obtained, leading to the release of 
lactate upon turnover. At high concentrations of pyruvate, the 
inactive LDH-NAD+-pyruvate binary complex is formed leading to 
LDH inhibition. The substrate inhibition is slightly affected by the 
aggregate, which displays a decreased Ki compared to the free 
enzyme.  
The minimal loading of the SavMatrix was determined using the 
purified LDH as Strep-tagged enzyme. The amount of matrix 
(0.5 mM FBS) was kept constant and the enzyme loading was 
varied incrementally from 0.16 to 1.34 equivalents vs. FBS sites 
of the SavMatrix (See Figure S4). At low LDH concentration, very 
little activity was detected; at 0.65 equivalents, the activity 
increased to 61 % of the maximal activity which was obtained at 
1.34 equivalents (100 %). Using a Boltzman fit, we determined 
that 0.56 ± 0.15 equivalents LDH vs. Sav FBS lead to 50 % 
activity. We conclude that minimum loading amount of the 
SavMatrix required to induce precipitation of enzyme is equal to 
0.5 eq. of enzyme vs FBS. 
 
Influence of the Oligomeric State of the Tagged Enzyme on 
Agglomeration 
While the tested monomeric enzymes bearing a single Streptag 
moiety do not led to the formation of an insoluble aggregate, 
precipitation can be achieved with multimeric enzymes upon 
mixing with SavMatrix. Insoluble aggregates are obtained for 
oligomeric enzymes presenting 2-6 biotin binding modules (SBP 
= two modules, SII = one module). Unfortunately, the monomeric 
BVMOs containing two biotin binding modules could not be 
isolated. Next, we verified that the designed SavMatrix afforded the 
best activity upon mixing with multimeric enzymes. For this 
purpose, (R)-TA was selected as model enzyme and was mixed 
with different Sav variants (0.5 mM Sav FBS): i) full-length 
Savwildtype ii) full-length Sav containing the StrepTactin mutation 
(hereafter SavTactin) iii) SavSpytag, iv) SavSpyCatch and v) SavMatrix 
(Figure 1). 
Figure 1. Relative activities of (R)-transaminase aggregates using different 
Sav-variants. SavTactin: Sav-wild type containing the SII-tag binding domain. 
Both the SavSpyTag and the Savwildtype do not form aggregates upon addition of 
(R)-TA and are thus not displayed. A normalized activity of 1 refers to 7990 U 
g-1dry aggregate. Reaction conditions: 3 ml reaction volume, 30°C (water 
temperate) using a VarianScan, sodium phosphate buffer (50 mM, pH 7.5) 
was preheated to 30°C, 5 mM (R)-α-methylbenzylamine and 5 mM pyruvate, 5 
min reaction time, reaction was initiated by addition of 10 µL precipitate-(R)-TA 
suspension followed by immediate mixing, monitored at 245 nm (a UV cuvette 
was used). 
 
Inspection of Figure 1 reveals that, except for both SavSpyTag and 
Savwildtype, the three other Sav-variants yield an active aggregate 
upon mixing with (R)-TA. The SavMatrix displayed the highest 
activity which was normalized to 1 for comparison. The SavTactin 
(tetramer) displayed only 20 % activity, suggesting that the 
oligomeric state of Sav plays a critical role in the aggregate’s 
activity. Accordingly, the SavSpyCatch displayed only 75 % activity 
compared to the aggregate resulting from SavMatrix. We 
speculate that the size of the Catch-protein (SavSpyCatch MW= 100 
kDa) favours precipitation upon addition of the tagged (R)-TA. 
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Cascades Resulting from Co-precipitation of Two Enzymes 
with SavMatrix 
Next, three enzymes were selected to engineer a cascade for 
the synthesis of enantiopure amines from prochiral ketones. For 
this purpose, the (R)-TA, GDH and LDH were selected as 
benchmark cascade (Scheme 2, F). The commercial, non-
tagged GDH was added as free enzyme to the suspension. A 
two-enzyme aggregate was assembled by co-precipitating (R)-
TA and LDH with SavMatrix (LDH/(R)-TAco hereafter). Both 
enzymes were mixed in equimolar amounts prior to mixing with 
equimolar amounts of FBS present in SavMatrix. After 3 h, the 
turbid suspension was centrifuged and the pellet was washed. 
The initial activities of both enzymes were determined 
individually using the respective standard substrates (Scheme 2, 
A and C). Gratifyingly, both enzymes were active in the 
aggregate. For all cascade experiments, the same starting 
activities of the (R)-TA and LDH were used. The LDH/(R)-TAco 
aggregate was compared to the soluble enzymes or to the 
separately-aggregated (R)-TA and LDH (LDH/(R)-TAsep 
hereafter). Remarkably, in the presence of the LDH/(R)-TAco 
aggregate, the yields of (R)-α-methylbenzylamine and (R)-2-
aminohexane were improved by 2.9 fold and 1.4 fold after 48 h 
respectively compared to the free enzymes and the LDH/(R)-
TAsep (Figure 2). Very similar yields were obtained for the free 
enzymes compared to the LDH/(R)-TAsep. This suggests a 
synergistic effect upon co-aggregating both enzymes within the 
SavMatrix. In all experiments, the enantioselectivity of the amine 
exceeded (R)-99 %.   
Figure 2. Amine concentration determined after 48 hours resulting from a 
cascade that combines (R)-TA and LDH in the presence of prochiral ketones. 
The free enzymes were compared to separately- (sep) and (co) aggregated 
(R)-TA and LDH. Commercial glucose dehydrogenase was added as soluble 
enzyme in all experiments. Reaction conditions: 0.2 ml reaction volume, 30°C, 
sodium phosphate buffer (50 mM, pH 7.5, 0.1 mM pyridoxalphoshat), ketone 
substrate (25 mM), DMSO (10 %), D-alanine (125 mM), D-glucose (150 mM), 
15 U ml-1 GDH-105 (Codexis, Redwood City), 3.5 U ml-1 LDH (activity against 
pyruvate) and 0.8 U ml-1 (R)-TA (activity against (R)-α-methylbenzylamine), the 
activities were normalized in each approach to allow for direct comparison. 
Analyses were performed by HPLC (conversion) and GC (enantioselectivity), 
see SI.	
 
Conclusions 
In summary, a novel matrix based on streptavidin for the 
formation of enzyme aggregates was designed. In the presence 
of enzymes bearing a Sav-binding peptide tag, catalytically 
active aggregates can be precipitated from E. coli crude cell 
extracts. Full recovery of the enzymatic activity was 
demonstrated for four enzymes from different classes. Several 
tag combinations were evaluated and the best was identified for 
each enzyme. The activity of the LDH aggregate was improved 
by nearly fivefold (up to 246188 U g-1dry aggregate). (R)-α-
methylbenzylamine and (R)-2-aminohexane were produced from 
a cascade which included LDH, (R)-TA and soluble GDH (for 
NADH regeneration). The yield was improved by nearly threefold 
for co-aggregates combining LDH and (R)-TA. To the best of our 
knowledge this study is the first example of an oligo-tetrameric 
SavMatrix, which is produced recombinantly in high yield. This 
method resembles a carrier-free approach, where a natural 
protein is used as crosslinking agent displaying specific affinity 
with the target proteins. The target protein can be obtained in 
higher purity in a one-step batch approach which may enable 
straightforward up-scaling. As all building blocks are genetically 
encoded, the system may be amenable to in vivo enzyme 
assembly. The method could thus be an attractive addition to the 
toolbox of synthetic biology to create artificial, scaffolded cell 
factories. 
Experimental Section 
For experimental details see supporting data. 
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